# Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

> **NCT00052455** · PHASE3 · COMPLETED · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 500 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** lomustine
- **DRUG:** procarbazine hydrochloride
- **DRUG:** temozolomide
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00052455
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2010-09
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052455, "Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00052455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*